The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS-Reference-Cited by-同舟云学术

The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS

Published:2017-12 Issue: Volume:8 Page:18-24
ISSN:2451-8654
Container-title:Contemporary Clinical Trials Communications
language:en
Short-container-title:Contemporary Clinical Trials Communications

Author:

Griffin Daniel,Benadiva Claudio^ORCID,Budinetz Tara,Sueldo Carolina,DiLuigi Andrea^ORCID,Nulsen John,Engmann Lawrence

Funder

Merck Sharp & Dohme (MSD) Corp., Roseland, New Jersey. USA

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference24 articles.

1. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study

2. Copenhagen Gn RHATWG. GnRH agonist for triggering of final oocyte maturation: time for a change of practice?;Humaidan;Hum. Reprod. Update,2011

3. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology;Youssef;Cochrane Database Syst. Rev.,2014

4. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome;Kol;Fertil. Steril.,2004

5. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study;Humaidan;Hum. Reprod.,2005

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. hCG Administration in Luteal Rescue: Intracavitary or Subcutaneously in Agonist Induced Ovulation in IVF Cycles;Clinical and Experimental Obstetrics & Gynecology;2023-05-22

2. Gonadotropin-releasing hormone agonist (alone or combined with human chorionic gonadotropin) vs. human chorionic gonadotropin alone for ovulation triggering during controlled ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis;F&S Reviews;2021-10

3. Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization;Fertility and Sterility;2019-09

4. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial;Journal of Ovarian Research;2019-01-26